Status In progress
Decision Selected
Process TA


Key events during the development of the guidance:

Date Update
28 October 2019 In progress. Referred 31 July 2017
02 October 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma. Following an update from the company, the timelines for this appraisal are to be confirmed in order to align with latest regulatory expectations. Therefore, NICE will continue to monitor development and will update interested parties as and when the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual